Table 2.
Treatment charachteristics.
| N. | % | |
|---|---|---|
| Local treatment pre-CapOx | ||
| Surgery (primary site) | 1 | 4 |
| Metastasectomy (hepatic resection) | 6 | 25 |
| Embolization | 2 | 8 |
| Chemoembolization | 1 | 4 |
| Systemic treatment other than CapOx | ||
| Somatostatin analogs +/- INF | 11 | 46 |
| Cisplatin or carboplatin + VP-16 or CPT-11 | 8 | 33 |
| Capecitabine | 5 | 21 |
| Lutecium radioligand therapy | 5 | 21 |
| Everolimus | 5 | 21 |
| Others | 6 | 25 |
| Cisplatin or carboplatin + taxane | 2 | 8 |
| 5-FU + adriamicin + streptozotocin (FAS) | 2 | 8 |
| Line of CapOx | ||
| First | 12 | 50 |
| Second | 6 | 25 |
| Third or beyond | 6 | 25 |
| Maintenance treatment post-CapOx | ||
| Capecitabine | 4 | 17 |
| Everolimus | 2 | 8 |
| Somatostatin analogs | 1 | 4 |
Median n. cycles of CapOx 6 (range 2-13). INF, interferon; VP-16, cisplatin or carboplatin associated with etoposide; CPT-11, irinotecan; 5-FU, fluorouracil; FAS, fluorouracil + adriamicin + streptozotocin.